Facts, Views & Vision
in ObGyn

Journal of the European Society for Gynaecological Endoscopy

esge_logo

The cost-effective, but forgotten, medical endometriosis therapy: a prospective, quasi-randomized study on  progestin therapy

T.C. Cezar 1 , K.W. Schweppe 2 , K.R. Pletzer 3 , S. Becker 4 , H. Krentel 5 , L.A. Torres -De La Roche 6 , R.L. De Wilde 7

1 Gynecology Consultant. Scientific Researcher at the University Hospital for Gynecology, Pius Hospital, University Medicine Oldenburg, Carl von Ossietzky University, Oldenburg, Germany;
2 Professor of the Clinic of Gynecology and Obstetrics at Ammerland – Klinik Westerstede, Westerstede, Germany;
3 Gynecology Consultant at Clinic for Gynecology and Obstetrics of Ammerland – Klinik Westerstede, Westerstede, Germany;
4 Professor and Director of the Clinic of Gynecology and Obstetrics Universitätsklinikum Frankfurt, Frankfurt, Germany;
5 Chief physician of the Clinic of Gynecology, Obstetrics and Oncology, St. Anna Hospital, Herne, Germany;
6 Gynecology Consultant. Scientific Researcher at the University Hospital for Gynecology, Pius Hospital, University Medicine Oldenburg, Carl von Ossietzky University, Oldenburg, Germany;
7 Professor and Head of the University Hospital for Gynecology, Pius Hospital, University Medicine Oldenburg, Carl von Ossietzky University, Oldenburg, Germany.

Keywords:

cost-effective, endometriosis, progestin, low-cost medication, compliance


Published online: Jul 24 2019

Abstract

Endometriosis represents nowadays a real burden for the patients as well as for the physicians, as it requires surgical and/or medical treatment, often long – termed and repeated. Moreover, the high costs necessary to diagnose and treat endometriosis represent a real economic burden, being comparable to other chronic diseases like diabetes or rheumatoid arthritis. Therefore, the physicians dealing with this disease should take into account not only the efficacy of the treatment, but also the economic aspects and patients compliance.

The present paper analyses the efficiency of progestins (lynestrenol and medrogestone) in endometriosis as a cost – effective, but forgotten medical therapy of the disease. Our study underlines the good tolerability of progestins, as they have limited side effects, the compliance of patients being high. They are also low-cost medications, which could represent an effective alternative method in the endometriosis treatment, especially in less – developed countries that cannot afford the higher therapeutic costs.